Study shows significant decline in prostate cancer diagnoses
the ONA take:
According to a new study published online in The Journal of Urology, researchers from Vanderbilt University Medical Center in Nashville, Tennessee, have found that new prostate cancer diagnoses in the United States dropped 28% in year following the United States Preventive Services Task Force (USPSTF) draft recommendation against routine prostate-specific antigen (PSA) screening for me.
For the study, researchers sought to assess the impact of the USPSTF's grade D recommendation in the year after the recommendation, which was announced in October 2011. Researchers used the National Cancer Database to identify new cancers diagnosed between January 2010 and December 2012.
Results showed that 12 months after the guidelines were published, new low-risk cancer diagnoses had decreased by 37.9%, new diagnoses of intermediate-risk disease dropped by 28.1%, and new diagnoses of high-risk prostate cancer decrease by 23.1%.
"The results raise concern that if this trend continues more men may be diagnosed at a point when their disease is advanced. Younger, healthier men with intermediate or high-risk disease would normally be candidates for aggressive local therapy and they may not be receiving a timely diagnosis under this policy," said first author Daniel Barocas, M.D., MPH, assistant professor of urological surgery and medicine.
Prostate cancer diagnoses in the United States dropped 28% in year following USPSTF draft recommendation.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|